BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

At the leading edge of drug development, digital health is starting to make waves, bringing products and tools that offer patients a new level of personalized medicine. At the same time, these technologies give the...
BioCentury | May 7, 2019
Company News

May 7 Company Quick Takes: Akcea, Bicycle/DDF, Arbutus, Celgene/Sutro, MDGH, Pfizer, Sanofi/Regeneron

Akcea's Waylivra approved in EU The European Commission granted conditional approval to Waylivra volanesorsen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) as an adjunct to diet in adult patients with familial chylomicronemia...
BioCentury | Apr 5, 2019
Emerging Company Profile

nGageIT: Breathing life into cancer diagnostics

nGageIT is developing breath-based cancer diagnostics for early detection of tumors at the point of care, without the time-consuming lab analysis that comparable technologies require. CEO Raj Reddy told BioCentury the inability of physicians to...
BioCentury | Feb 13, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Infectious In vitro and mosquito studies identified a quinazoline-based agonist of A. aegypti NPYLR7 that could help prevent A. aegypti mosquito bites and associated infections. In vitro screening of a compound library in agonistic...
BioCentury | Feb 8, 2019
Finance

Medicxi’s orexin dream deal

Sleep disorder spinouts Orexia Ltd. and Inexia Ltd. were created to marry Medicxi’s keen interest in agonizing orexin and Heptares Therapeutics Ltd.’s desire to find creative ways to fund its pipeline. Medicxi will invest up...
BioCentury | Feb 7, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
BioCentury | Feb 4, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
BioCentury | Nov 3, 2017
Clinical News

AZ's asthma candidate misses again in Phase III

AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in both the Phase III STRATOS 2 and TROPOS trials to treat severe uncontrolled asthma. The pharma could not be reached for next steps...
BioCentury | Nov 1, 2017
Clinical News

AZ's asthma candidate misses again in Phase III

AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in both the Phase III STRATOS 2 and TROPOS trials to treat severe uncontrolled asthma. The pharma could not be reached for next steps...
BioCentury | Oct 20, 2017
Financial News

OptiNose raises $138M in IPO

OptiNose Inc. (NASDAQ:OPTN) raised $138 million through the sale of 8.6 million shares at $16 in an IPO underwritten by Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets. The price was at the...
Items per page:
1 - 10 of 213
BioCentury | Aug 31, 2019
Product Development

Digital tech meets the patient: first movers are bringing digital to biopharma

At the leading edge of drug development, digital health is starting to make waves, bringing products and tools that offer patients a new level of personalized medicine. At the same time, these technologies give the...
BioCentury | May 7, 2019
Company News

May 7 Company Quick Takes: Akcea, Bicycle/DDF, Arbutus, Celgene/Sutro, MDGH, Pfizer, Sanofi/Regeneron

Akcea's Waylivra approved in EU The European Commission granted conditional approval to Waylivra volanesorsen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) as an adjunct to diet in adult patients with familial chylomicronemia...
BioCentury | Apr 5, 2019
Emerging Company Profile

nGageIT: Breathing life into cancer diagnostics

nGageIT is developing breath-based cancer diagnostics for early detection of tumors at the point of care, without the time-consuming lab analysis that comparable technologies require. CEO Raj Reddy told BioCentury the inability of physicians to...
BioCentury | Feb 13, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Infectious In vitro and mosquito studies identified a quinazoline-based agonist of A. aegypti NPYLR7 that could help prevent A. aegypti mosquito bites and associated infections. In vitro screening of a compound library in agonistic...
BioCentury | Feb 8, 2019
Finance

Medicxi’s orexin dream deal

Sleep disorder spinouts Orexia Ltd. and Inexia Ltd. were created to marry Medicxi’s keen interest in agonizing orexin and Heptares Therapeutics Ltd.’s desire to find creative ways to fund its pipeline. Medicxi will invest up...
BioCentury | Feb 7, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
BioCentury | Feb 4, 2019
Company News

Heptares, Medicxi spin out narcolepsy companies

The Heptares Therapeutics Ltd. unit of Sosei Group Corp. (Tokyo:4565) partnered with life sciences VC Medicxi Ventures to spin out two asset-centric newcos, Orexia Ltd. and Inexia Ltd., to develop preclinical orexin agonists to treat...
BioCentury | Nov 3, 2017
Clinical News

AZ's asthma candidate misses again in Phase III

AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in both the Phase III STRATOS 2 and TROPOS trials to treat severe uncontrolled asthma. The pharma could not be reached for next steps...
BioCentury | Nov 1, 2017
Clinical News

AZ's asthma candidate misses again in Phase III

AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in both the Phase III STRATOS 2 and TROPOS trials to treat severe uncontrolled asthma. The pharma could not be reached for next steps...
BioCentury | Oct 20, 2017
Financial News

OptiNose raises $138M in IPO

OptiNose Inc. (NASDAQ:OPTN) raised $138 million through the sale of 8.6 million shares at $16 in an IPO underwritten by Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets. The price was at the...
Items per page:
1 - 10 of 213